SRXH
SRx Health Solutions Inc.
There isn't enough reported data to score SRXH yet.
SRXH Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
SRXH's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
SRXH PE Valuation
SRXH has no meaningful PE right now: it lost money over the past year.
SRXH Forward outlook
There aren't enough analyst estimates for SRXH to show an outlook.
SRXH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$921.78 | +$1,209.78 |
| Q2 2024 | -$1,052.00 | +$1,412.00 |
| Q1 2024 | -$1,380.00 | +$1,181.78 |
| Q4 2023 | -$1,435.11 | +$1,185.33 |
| Q3 2023 | -$2,131.56 | +$234.66 |
| Q2 2023 | -$2,464.00 | -$293.33 |
| Q1 2023 | -$2,561.78 | -670% |
| Q4 2022 | -$2,620.44 | -$645.33 |
SRXH is still losing money, but far less than before: $921.78 per share over the past year, against $14,549.33 at its worst in early 2021.
SRXH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.4M | -70% |
| Q1 2026 | $3.4M | -52% |
| Q4 2025 | $2.8M | -61% |
| Q2 2025 | $11.4M | +34% |
| Q1 2025 | $7.2M | -9.4% |
| Q4 2024 | $7.2M | +26% |
| Q3 2024 | $11.4M | -13% |
| Q2 2024 | $8.5M | -19% |
SRXH's revenue has slid since its 2022 peak: $3M last quarter, down 53% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -94% | +58 points |
| Q1 2026 | -53% | -38 points |
| Q4 2025 | -135% | -112 points |
| Q2 2025 | -152% | -144 points |
| Q1 2025 | -15% | +16 points |
| Q4 2024 | -23% | +200 points |
| Q3 2024 | -9.9% | +10 points |
| Q2 2024 | -8.5% | +16 points |
SRXH's operating margin was −94% last quarter, down 79 points from the same quarter a year ago.
SRXH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$6.6M | -1858% |
| Q4 2025 | -$2.9M | -$1.7M |
| Q1 2025 | $377K | +$1.4M |
| Q4 2024 | -$1.2M | -220% |
| Q3 2024 | -$2.2M | -745% |
| Q2 2024 | $5K | -98% |
| Q1 2024 | -$1M | +$474K |
| Q4 2023 | $983K | +$3.6M |
SRXH has burned cash in most quarters: −$10M over the past year, against −$2M the year before.
SRXH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +65% | +222K shares |
| 1 year | +2706% | +542K shares |
| 3 years | +3654% | +547K shares |
SRXH has 562,284 diluted shares, up 2706% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2022 | — |
| Q4 2021 | $327,000 |
SRXH Net Leverage
SRXH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SRXH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.1 | Oversold |
| Stochastic | 11.2 | Oversold |
SRXH's weekly RSI is 22 (oversold) and its Stochastic is 11 (oversold).
SRXH PE vs Healthcare Sector
SRXH has no meaningful PE right now: it lost money over the past year.
SRXH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.22 | 23% below |
| 20 week MA | $1.74 | 46% below |
| 50 week MA | $6.72 | 86% below |
SRXH is in a downtrend: it's below all three of its weekly moving averages, and 86% below its 50-week average.
SRXH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $121.3 | $16.9 | -86% |
| 2026 YTD | $16.9 | $0.94 | -94% |
SRXH has finished every year since 2025 lower, and it's down 94% so far in 2026.